Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.
Under the agreement, the company receives a non-exclusive worldwide license to use the StabyExpress™ technology for enzyme production in GMP conditions. In exchange, Delphi is eligible to receive upfront and milestone payments associated with the development of the product that utilize the StabyExpress® technology, as well as royalties on sales of such product.
Cédric Szpirer PhD, Delphi Genetics Founder and CEO, explained: "This is Delphi's first licensing agreement that covers the use of the StabyExpress® technology for protein production in the field of food industry. It is an additional proof that the technology is usable for any production of recombinant protein in E. coli including pharmaceutical bioproductions and industrial biotechnology. The StabyExpress® technology allows to produce (i) higher yields of recombinant proteins and (ii) without the use of antibiotic resistance genes. These advantages were clearly identified by our new partner. The non-exclusive nature of this agreement enables us to consider similar collaborations with other strategic partners."
Previously, Delphi Genetics announced existing licensing agreements with Sanofi-Pasteur, GSK and a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada.